Efficacy, Safety, and Tolerability of Secukinumab in Psoriatic Arthritis: A Systematic Review and Meta-Analysis.

Ann PharmacotherMay 13, 2026 (epub)
Clinical ResearchRheumatology

Muhammad Saad Khan, Saim Mahmood Khan, Rabia Farooq et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the efficacy and safety of secukinumab in adults with active psoriatic arthritis (PsA) by analyzing randomized controlled trials. The study found that secukinumab significantly improved ACR20 and ACR50 response rates and reduced HAQ-DI scores compared to placebo, indicating its effectiveness in managing PsA.

Key findings

  • Secukinumab significantly improved ACR20 response rates compared to placebo.
  • Secukinumab significantly improved ACR50 response rates compared to placebo.
  • HAQ-DI scores were significantly reduced with secukinumab compared to placebo.
  • No significant increase in overall adverse events or treatment discontinuation was observed.

Why it matters

The findings highlight secukinumab as an effective and well-tolerated treatment option for patients with active psoriatic arthritis, particularly those who have not responded adequately to conventional therapies. This supports personalized treatment approaches in managing the disease.

Source

PubMed · PMID 42130150

Published in Ann Pharmacother. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Rheumatology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.